The multicenter observational study of systemic chemotherapy for gastrointestinal and hepatobiliary-pancreatic poorly differentiated neuroendocrine carcinoma.

The multicenter observational study of systemic chemotherapy for gastrointestinal and hepatobiliary-pancreatic poorly differentiated neuroendocrine carcinoma. - The multicenter observational study of systemic chemotherapy for gastrointestinal and hepatobiliary-pancreatic poorly differentiated neuroendocrine carcinoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005176

Enrollment

300

Registered

2011-03-04

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal and hepatobiliary-pancreatic poorly differentiated neuroendocrine carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: * The poorly-differentiated neuroendocrine carcinoma arising from esophagus,stomach, duodenum, colorectum, liver, biriary tract, or pancreas. * Chemotherapy was performed for poorly-differentiated neuroendocrine carcinoma.

Exclusion criteria

Exclusion criteria: malignant carcinoid insulinoma, gastrinoma, VIPoma islet cell carcinoma

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Progression-free survival, Overall survival, Time to progression	—

Countries

Japan

Contacts

Public ContactTomohiro Yamaguchi

National Cancer Center Hospital ,Tokyo,Japan Division of Hepatobiliary and Pancreatic Oncology

toyamagu@ncc.go.jp

Outcome results